The U.S. Food and Drug Administration (FDA) approved Adasuve (loxapine) for the acute treatment of agitation caused by schizophrenia or bipolar 1 disorder.
Adasuve is the first non-injectable form of therapy for symptoms of agitation.
Two phase 3 clinical trials involving 1,600 patients were carried out with either Adasuve or placebo as the options. At the 10 mg dose, symptoms of agitations dropped dramatically.
I wrote about this drug earlier last year. It can cause bronchospasm and patients with asthma and chronic obstructive pulmonary disease (COPD) who take Adasuve are at a higher risk of bronchospasm. This condition causes severe breathing problems and can result in respiratory arrest or respiratory diseases.
The Adasuve Risk Evaluation and Mitigation Strategy (Adasuve REMS) will monitor the drug's administration.
(Adasuve loxapine Inhalation Powder Approved for Schizophrenia or Bipolar Agitation, retrieved on January 1, 2013 from http://www.medicalnewstoday.com/articles/254474.php)
Researchers at the University of Cambridge and Queen Mary University in London analyzed data that showed high rates of schizophrenia in urban regions are related to an increase in inequality and deprivation. The illness was more common in poorer urban areas with high population densities.
427 people between the ages of 18 and 62 who experienced their first psychotic episode between 1996 and 2000 were researched.
Thus: schizophrenia is not only biological, it is affected by social, economic and political factors as well, according to the research.
Lead study author Dr. James Kirkbride from the University of Cambridge suggests, "Both absolute and relative levels of deprivation predict the incidence of schizophrenia."
Could social causes be critical and key elements that not only cause mental health conditions but help people overcome them?
Previous studies indicated that health and social outcomes are better in societies that are more equal.
(Is schizophrenia connected to deprivation? retrieved on January 8, 2013 from http://www.mentalwellnesstoday/com . . .)
A brain imaging study shows patients with first-episode schizophrenia (FES) exhibit widespread white matter abnormalities.
Sang-Hyuk Lee (CHA University, Seongnam Kyounggi, South Korea) and researchers found a positive link between white matter values in a number of brain regions and positive and negative symptoms and executive function.
A diffusion tensor imaging study of 17 FES patients and 17 age- and gender-matched mentally healthy controls showed this correlation.
(Extensive white matter abnormalities in early schizophrenia, retrieved on January 5, 2013 from http://www.news-medical.net/news . . .)
An Italian research study shows greater hippocampal deflation is linked with increased illness severity and poorer social functioning in individuals with schizophrenia.
Greater bilateral hippocampal shape deflation was linked with increased length of illness and severity of positive and negative symptoms, as well as reduced educational level, quality of life and general health status in patients with schizophrenia.
Magnetic resonance imaging produced 3D brain maps of 67 patients with schizophrenia and 72 mentally health controls.
The researchers suggest the findings could lead to determining those individuals who would benefit from treatment such as psychosocial stimulation, cognitive rehabilitation or physical exercise.
The effects of these clinical interventions could be monitored to lead to better clinical and social outcomes.
(Hippocampal size linked to illness severity, functioning in schizophrenia retrieved on January 5, 2013 from http://www.news-medical.net/news . . .)
Published On: January 08, 2013